### ü´Å Pulmonary Medicine: Long-Acting Bronchodilator Therapy in COPD

#### ‚úÖ True Statements
1. A **long-acting bronchodilator** is recommended for patients with **chronic obstructive pulmonary disease (COPD)** who have mild disease with frequent symptoms or in whom a short-acting bronchodilator alone has been ineffective.
2. The **Global Initiative for Chronic Obstructive Lung Disease (GOLD) combined assessment** stratifies patients into categories **A, B, and E** based on **symptom severity** and **history of exacerbations**.
3. **GOLD group A** is defined as **mild symptoms** with **one or fewer exacerbations per year not requiring hospitalization**.
4. Appropriate therapy for **GOLD group A** COPD includes either a **short-acting bronchodilator** or a **long-acting bronchodilator**.
5. In **GOLD group A**, a **long-acting bronchodilator** is generally preferred, although **short-acting bronchodilators** may be sufficient in very mild or infrequent symptoms.
6. **Long-acting Œ≤2-agonists (LABAs)** and **long-acting muscarinic antagonists (LAMAs)** are both appropriate treatment options for patients in **GOLD group A**.
7. **GOLD group B** patients have a greater symptom burden than group A despite both groups having low exacerbation risk.
8. In **GOLD group B**, combination therapy with a **LABA plus a LAMA** is recommended.
9. Patients with **two or more exacerbations** or **one or more exacerbations leading to hospitalization per year** are categorized as **GOLD group E**, regardless of symptom severity.
10. **GOLD group E** patients should receive combination therapy with a **LABA plus a LAMA**.
11. In **GOLD group E**, **triple therapy** with a **LABA, LAMA, and inhaled glucocorticoid** may be considered if the **blood eosinophil count is ‚â•300/ŒºL**.
12. **Short-acting bronchodilators** such as **albuterol** are appropriate as **rescue inhalers** in COPD and may be sufficient for **very mild disease**.
13. Most patients with **COPD** require **controller therapy** rather than **as-needed short-acting agents alone**.

#### üí¨ Extra
2. The GOLD model incorporates both **symptoms** (eg, Modified Medical Research Council Dyspnea Scale, COPD Assessment Test) and **exacerbation history**.
3. Group A corresponds to **low exacerbation risk** and **low symptom burden**.
7. Both groups A and B are ‚Äúlow risk,‚Äù but **group B** has **greater dyspnea or quality-of-life impact**.
11. Blood eosinophils are used as a biomarker to predict **inhaled glucocorticoid response**.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #COPD #Bronchodilator #LABA #LAMA #GOLDGuidelines #AmbulatoryCare

#### üìö Reference
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.

#### üÜî Question ID
PMMCQ24052

#### üïí Last Updated
June 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Airways Disease, COPD, Management of COPD, Pharmacologic Therapy for COPD, Bronchodilators

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. Inhaled **bronchodilators** for COPD include **Œ≤2-agonists** and **anticholinergics/antimuscarinic agents**, both available as **short-acting** and **long-acting** inhalers.
2. Both **Œ≤2-agonists** and **anticholinergics** improve **symptoms** and **expiratory airflow** in COPD.
3. **Short-acting Œ≤2-agonists (SABAs)** and **short-acting muscarinic antagonists (SAMAs)** result in **similar bronchodilation** and either can be used as **monotherapy**.
4. **Combination therapy** with a **SABA and a SAMA** produces **greater bronchodilation and expiratory airflow** than either agent alone and may lead to **symptom benefit** in select COPD patients.
5. If **short-acting bronchodilators** are insufficient to control symptoms in COPD, a **long-acting bronchodilator** (LABA or LAMA) can be added.
6. The choice of a **long-acting bronchodilator inhaler** should consider **patient preference**, **physician preference**, **adverse effects**, and **cost**.
7. If symptoms persist on **long-acting bronchodilator monotherapy**, adding a **second long-acting bronchodilator** from the **alternate class** may improve symptoms.
8. **Long-acting bronchodilators alone should not be used** in patients with a **history or diagnosis of asthma**, unless combined with an **inhaled glucocorticoid**, because **LABA monotherapy in asthma increases mortality risk**.

#### üí¨ Extra
4. Combining SABA + SAMA provides **synergistic bronchodilation** compared to either drug alone.
6. Real-world factors such as **inhaler device usability** and **insurance coverage** influence therapy choice.
8. The **safety restriction** is based on evidence of **increased asthma-related deaths** with LABA monotherapy.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #COPD #Bronchodilator #SABA #SAMA #LABA #LAMA #AsthmaSafety

---

#### üóæ Supplemental Tables

<!-- GOLD Model Table -->
<table>
  <caption><strong>GOLD Model for Classifying Severity of Disease in COPD</strong></caption>
  <thead>
    <tr>
      <th>Symptoms</th>
      <th>Exacerbation History</th>
      <th>Patient Group</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Low (mMRC 0-1 or CAT &lt;10)</td>
      <td>0-1 per year, no hospitalization</td>
      <td>A</td>
    </tr>
    <tr>
      <td>High (mMRC ‚â•2 or CAT ‚â•10)</td>
      <td>0-1 per year, no hospitalization</td>
      <td>B</td>
    </tr>
    <tr>
      <td>Any symptom level</td>
      <td>‚â•2 per year or ‚â•1 hospitalization</td>
      <td>E</td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: GOLD Model for Classifying Severity of Disease in COPD)
1. Patients with **mMRC 0‚Äì1 or CAT <10** and **0‚Äì1 exacerbations per year without hospitalization** are classified as **group A**.
2. Patients with **mMRC ‚â•2 or CAT ‚â•10** and **0‚Äì1 exacerbations per year without hospitalization** are classified as **group B**.
3. Patients with **any symptom level** and **‚â•2 exacerbations per year** or **‚â•1 hospitalization per year** are classified as **group E**.

---

<!-- Recommended Therapy Table -->
<table>
  <caption><strong>Recommended Therapy for COPD by GOLD Patient Group</strong></caption>
  <thead>
    <tr>
      <th>Patient Group</th>
      <th>Recommended Therapy</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>A</td>
      <td>Short- or long-acting bronchodilator</td>
    </tr>
    <tr>
      <td>B</td>
      <td>LABA + LAMA</td>
    </tr>
    <tr>
      <td>E</td>
      <td>LABA + LAMA; consider LABA + LAMA + inhaled glucocorticoid if eosinophils ‚â•300/ŒºL</td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Recommended Therapy for COPD by GOLD Patient Group)
1. **Group A** COPD patients should be treated with either a **short-acting bronchodilator** or a **long-acting bronchodilator**.
2. **Group B** COPD patients should receive combination therapy with a **LABA plus a LAMA**.
3. **Group E** COPD patients should receive **LABA plus LAMA therapy**, with **triple therapy (LABA + LAMA + inhaled glucocorticoid)** considered if **blood eosinophil count ‚â•300/ŒºL**.
